Log in


Your Resource for Neurotherapeutics Discovery and Development


ASENT Announces New Partnership with Elsevier to Publish Neurotherapeutics, Beginning January 2024

ASENT is excited to announce that beginning in 2024, Neurotherapeutics will be published in partnership with Elsevier. This collaboration offers new opportunities by combining the expertise of ASENT’s global authors, editors, and peer reviewers and Elsevier’s state-of-the-art technology. These combined efforts will position ASENT for continued growth, increased visibility, and raised awareness of the Journal’s primary goal of advancing and furthering the dissemination of science and to promote the quality science related to therapies for diseases and disorders of the nervous system around the globe.

Neurotherapeutics’ preeminent international editorial board will continue under the leadership of Editor-in-Chief Dr. M. Maral Mouradian and ensures that this high quality, peer-reviewed journal will be an authoritative resource for the community it serves. In addition, to strive for continued quality and market growth, Neurotherapeutics will move to a fully Gold Open Access (OA) publishing model. 


The American Society for Experimental Neurotherapeutics (ASENT) is an independent non-profit organization established in 1997 by leaders in academia, government, advocacy and industry to facilitate the process by which new therapies are made available to patients with neurological disorders. Its primary goal is to encourage and advance the development of improved therapies for diseases and disorders of the nervous system.

ASENT engages in scientific exchanges to encourage contacts between those involved in the discovery and development of neurotherapeutics and to provide opportunities for dialogue between the interested groups.  The society organizes education and training and publishes a journal for healthcare practitioners, scientists and officials participating in the neurotherapeutics field, which serves as a forum for its members and interested groups addressing diverse issues.


Andrew J. Cole, M.D., F.R.C.P.(C.), our new President of ASENT.  Dr. Cole is Professor of Neurology at Harvard Medical School and Director of the Massachusetts General Hospital (MGH) Epilepsy Service, Chief of the Division of Clinical Neurophysiology, and Vice Chair of the MGH Neurology Service at Massachusetts General Hospital.  


ASENT is honored to have M. Maral Mouradian, MD, as the NEUROTHERAPEUTICS journal Editor in Chief. Dr Mouradian is the William Dow Lovett Professor of Neurology; Director of the RWJMS Institute for Neurological Therapeutics; and Vice Chancellor for Faculty Development, Rutgers Biomedical and Health Sciences - Robert Wood Johnson Medical School


Sharon Tamir, Vice President, Head of Neuro-oncology & Myelofibrosis at Karyopharm Therapeutics Inc. and Dietrich Haubenberger, MD, Executive Medical Director for Clinical Development at Neurocrine Biosciences have generously agreed to lead our Scientific Program Committee for the ASENT Annual Meeting.  


Post your neurotherapeutics, neurology or neuroscience job on the ASENT Career Center. Prices start at $299 for posting to run for 60 days. Attract diverse candidates, veterans, and maximize distribution to job aggregator websites via this unique career center in the neurotherapeutics space.


Clinical Trials Course Travel Grants

DONATE TO SUPPORT TRAVEL GRANTS: These funds will be utilized to support travel awards to participate in the forthcoming Clinical Trials Course.
Collected: $625.00
Goal: $100,000.00

Featured Members


American Society for 
Experimental Neurotherapeutics

The American Society for Experimental Neurotherapeutics (ASENT) is a 501(c)3 non-profit organization. 

Powered by Wild Apricot Membership Software